HC Wainwright Has Positive Outlook for Insmed Q3 Earnings

Insmed, Inc. (NASDAQ:INSM) – Research analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Insmed in a research report issued on Monday, October 12th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright has a “Buy” rating and a $220.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($1.26) EPS.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The business had revenue of $425.49 million during the quarter, compared to analyst estimates of $395.50 million. During the same quarter in the previous year, the business posted ($1.70) EPS. The company’s quarterly revenue was up 296.1% compared to the same quarter last year.

Several other equities analysts have also issued reports on the stock. Barclays cut their price objective on shares of Insmed from $237.00 to $207.00 and set an “overweight” rating on the stock in a report on Wednesday, September 30th. Wells Fargo & Company boosted their price objective on shares of Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Guggenheim lowered their target price on Insmed from $207.00 to $205.00 and set a “buy” rating for the company in a report on Friday, August 7th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Insmed in a research report on Tuesday, October 6th. Finally, Bank of America reaffirmed a “buy” rating and set a $207.00 target price on shares of Insmed in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $200.30.

Insmed Price Performance

Shares of INSM opened at $96.79 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The company has a 50 day moving average price of $120.16 and a 200-day moving average price of $119.10. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The stock has a market capitalization of $21.14 billion, a PE ratio of -23.55 and a beta of 0.83.

Insider Transactions at Insmed

In other Insmed news, Director David Brennan sold 25,000 shares of the stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Roger Adsett sold 239,850 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Insmed

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sei Investments Co. raised its position in Insmed by 56.8% during the first quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after acquiring an additional 505,624 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Insmed in the second quarter valued at approximately $139,966,000. Castle Hook Partners LP boosted its position in Insmed by 14.9% in the 4th quarter. Castle Hook Partners LP now owns 1,253,568 shares of the biopharmaceutical company’s stock worth $218,171,000 after purchasing an additional 162,163 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in Insmed by 14.9% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,102,248 shares of the biopharmaceutical company’s stock worth $178,659,000 after purchasing an additional 143,285 shares in the last quarter. Finally, NWI Management LP boosted its position in Insmed by 2.6% in the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock worth $165,809,000 after purchasing an additional 25,540 shares in the last quarter.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $220 price target, implying substantial upside from recent trading levels. The firm also slightly raised its FY2027 EPS estimate to $1.63 from $1.62. Insmed’s Buy Rating Reaffirmed at HC Wainwright
• Positive Sentiment: Investors purchased 8,177 call options on Tuesday, more than triple the average volume of 2,676 contracts. The unusually high call activity may indicate increased speculative interest or expectations for a rebound, although options positioning does not guarantee future gains.
• Neutral Sentiment: Analyst coverage remains divided: HC Wainwright is bullish, while Wolfe Research moved to a more neutral stance. This disagreement may contribute to elevated volatility as investors reassess Insmed’s valuation and growth outlook. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Wolfe Research downgraded Insmed from Outperform to Peer Perform, removing a bullish endorsement and likely pressuring the stock. The downgrade was highlighted as the main catalyst behind the shares’ decline. Insmed Shares Fall After Wolfe Research Downgrade

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.